We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Oncology Panel Votes 7-2 to Maintain Accelerated Approval for Roche’s Tecentriq
FDA Oncology Panel Votes 7-2 to Maintain Accelerated Approval for Roche’s Tecentriq
An independent expert panel of the FDA voted 7-2 Tuesday to allow Roche’s Tecentriq (atezolizumab) to remain approved for treating PD-L1-positive unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) alongside nab-paclitaxel as further trial data are generated.